2024
Parent-Clinician Communication and Prolonged Grief in Parents Whose Child Died From Cancer
Ouyang N, Baker J, Ananth P, Knobf M, Snaman J, Feder S. Parent-Clinician Communication and Prolonged Grief in Parents Whose Child Died From Cancer. Journal Of Pain And Symptom Management 2024, 68: 516-524.e1. PMID: 39142495, DOI: 10.1016/j.jpainsymman.2024.08.003.Peer-Reviewed Original ResearchEnd-of-lifeParent-clinician communicationProlonged grief symptomsGrief symptomsChild's end-of-lifeCross-sectional survey of parents of childrenEnd-of-life careHigh-quality end-of-lifeProlonged griefSum scoreSurvey of parents of childrenCross-sectional surveyParents of childrenAdequate prognostic informationBereaved parentsPrognostic informationChild deathsParents' experiencesMultiple linear regressionPG-13Analyzed dataLinear regressionAssociationGriefChildren
2018
Provider Perspectives on Use of Medical Marijuana in Children With Cancer
Ananth P, Ma C, Al-Sayegh H, Kroon L, Klein V, Wharton C, Hallez E, Braun I, Michelson K, Rosenberg AR, London W, Wolfe J. Provider Perspectives on Use of Medical Marijuana in Children With Cancer. Pediatrics 2018, 141: e20170559. PMID: 29233937, PMCID: PMC5744275, DOI: 10.1542/peds.2017-0559.Peer-Reviewed Original ResearchConceptsPediatric oncology providersMedical marijuanaOncology providersMM useProvider perspectivesCancer-directed therapyPercent of providersCross-sectional surveyLogistic regression modelsWilcoxon rank testSupportive careMedian ageOral formulationMM practiceSerious illnessMost providersGroup comparisonsCancerPrevious monthRank testState-specific regulationsChildrenRegression modelsImportant barriersGreatest barrier
2017
Influence of early phase clinical trial enrollment on patterns of end‐of‐life care for children with advanced cancer
Ananth P, Monsereenusorn C, Ma C, Al‐Sayegh H, Wolfe J, Rodriguez‐Galindo C. Influence of early phase clinical trial enrollment on patterns of end‐of‐life care for children with advanced cancer. Pediatric Blood & Cancer 2017, 65 PMID: 28771913, DOI: 10.1002/pbc.26748.Peer-Reviewed Original ResearchConceptsEarly phase clinical trialsTrial enrollmentAdvanced cancerHealthcare utilizationLife careRetrospective cohort studyPediatric oncology patientsClinical trial enrollmentPhase clinical trialsPatterns of endNeP patientsBaseline characteristicsCohort studyOncology patientsEP patientsPPC consultationClinical trialsCare receiptPatientsCancerEnrollmentCareFuture studiesChildrenEOLC
2016
Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis
Ananth P, Werger A, Voss S, Rodriguez‐Galindo C, Janeway KA. Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatric Blood & Cancer 2016, 64: e26375. PMID: 27905688, DOI: 10.1002/pbc.26375.Peer-Reviewed Original ResearchConceptsProgression-free intervalLiposomal doxorubicinDesmoid fibromatosisLonger progression-free intervalMedian progression-free intervalRetrospective case seriesImportant treatment optionClinical responseMedical therapyCase seriesTumor sizeTreatment optionsEffective treatmentFibromatosisTreatmentChildrenMedications